Delladetsima J K, Makris F, Psichogiou M, Kostakis A, Hatzakis A, Boletis J N
Department of Pathology, Laiko General Hospital, Athens, Greece.
Liver. 2001 Apr;21(2):81-8. doi: 10.1034/j.1600-0676.2001.021002081.x.
BACKGROUND/AIMS: Bile duct cells are known to be susceptible to hepatitis B and C virus, while it has been recently suggested that hepatitis B virus (HBV) and hepatitis C virus (HCV) infection may have a direct role in the pathogenesis of vanishing bile duct syndrome (VBDS) after liver transplantation. We report the development of a cholestatic syndrome associated with bile duct damage and loss in four HCV-infected renal transplant recipients.
All four patients were followed up biochemically, serologically and with consecutive liver biopsies. Serum HCV RNA was quantitatively assessed and genotyping was performed.
Three patients were anti-HCV negative and one was anti-HCV/HBsAg positive at the time of transplantation and received the combination of methylprednisolone, azathioprine and cyclosporine A. Two patients became anti-HCV positive 1 year and one patient 3 years post-transplantation. Elevation of the cholestatic enzymes appeared simultaneously with seroconversion, or 2-4 years later, and was related to lesions of the small-sized interlobular bile ducts. Early bile duct lesions were characterized by degenerative changes of the epithelium. Late and more severe bile duct damage was associated with bile duct loss. The progression of the cholestatic syndrome coincided with high HCV RNA serum levels, while HCV genotype was 1a and 1b. Two patients (one with HBV co-infection) developed progressive VBDS and died of liver failure 2 and 3 years after biochemical onset. One patient, despite developing VBDS within a 10-month period, showed marked improvement of liver function after cessation of immunosuppression because of graft loss. The fourth patient, who had mild biochemical and histological bile duct changes, almost normalized liver function tests after withdrawal of azathioprine.
A progressive cholestatic syndrome due to bile duct damage and loss may develop in renal transplant patients with HCV infection. The occurrence of the lesions after the appearance of anti-HCV antibodies and the high HCV RNA levels are indicative of viral involvement in the pathogenesis. Withdrawal of immunosuppressive therapy may have a beneficial effect on the outcome of the disease.
背景/目的:已知胆管细胞对乙型肝炎病毒和丙型肝炎病毒易感,而最近有研究表明,乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染可能在肝移植后消失性胆管综合征(VBDS)的发病机制中起直接作用。我们报告了4例丙型肝炎病毒感染的肾移植受者出现与胆管损伤和丢失相关的胆汁淤积综合征。
对所有4例患者进行生化、血清学随访,并连续进行肝活检。对血清HCV RNA进行定量评估并进行基因分型。
3例患者移植时抗-HCV阴性,1例抗-HCV/HBsAg阳性,接受甲泼尼龙、硫唑嘌呤和环孢素A联合治疗。2例患者移植后1年抗-HCV转为阳性,1例患者移植后3年抗-HCV转为阳性。胆汁淤积酶升高与血清学转换同时出现,或在2 - 4年后出现,且与小叶间小胆管病变有关。早期胆管病变以上皮细胞变性改变为特征。晚期更严重的胆管损伤与胆管丢失有关。胆汁淤积综合征的进展与高HCV RNA血清水平一致,HCV基因型为1a和1b。2例患者(1例合并HBV感染)发生进行性VBDS,并在生化指标出现异常后2年和3年死于肝功能衰竭。1例患者尽管在10个月内发生了VBDS,但由于移植肾丢失而停止免疫抑制治疗后,肝功能明显改善。第4例患者有轻度生化和组织学胆管改变,停用硫唑嘌呤后肝功能检查几乎恢复正常。
丙型肝炎病毒感染的肾移植患者可能发生因胆管损伤和丢失导致的进行性胆汁淤积综合征。抗-HCV抗体出现后及高HCV RNA水平时出现病变,提示病毒参与发病机制。停用免疫抑制治疗可能对疾病预后有有益影响。